Zynex Revenue 2006-2018 | ZYXI

Zynex revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Zynex Annual Revenue
(Millions of US $)
2018 $32
2017 $23
2016 $13
2015 $12
2014 $11
2013 $22
2012 $40
2011 $34
2010 $24
2009 $19
2008 $12
2007 $8
2006 $3
2005 $2
Zynex Quarterly Revenue
(Millions of US $)
Q4 2018 $9
Q3 2018 $8
Q2 2018 $8
Q1 2018 $7
Q4 2017 $8
Q3 2017 $7
Q2 2017 $5
Q1 2017 $3
Q4 2016 $3
Q3 2016 $4
Q2 2016 $3
Q1 2016 $3
Q4 2015 $3
Q3 2015 $3
Q2 2015 $3
Q1 2015 $3
Q4 2014 $2
Q3 2014 $4
Q2 2014 $1
Q1 2014 $3
Q4 2013 $3
Q3 2013 $5
Q2 2013 $5
Q1 2013 $8
Q4 2012 $11
Q3 2012 $10
Q2 2012 $10
Q1 2012 $9
Q4 2011 $10
Q3 2011 $9
Q2 2011 $8
Q1 2011 $7
Q4 2010 $7
Q3 2010 $7
Q2 2010 $6
Q1 2010 $5
Q4 2009 $5
Q3 2009 $5
Q2 2009 $4
Q1 2009 $4
Q4 2008 $4
Q3 2008 $2
Q2 2008 $3
Q1 2008 $3
Q4 2007 $2
Q3 2007 $2
Q2 2007 $3
Q1 2007 $1
Q4 2006 $1
Q3 2006 $1
Q2 2006 $1
Q1 2006 $1
Q4 2005 $0
Q3 2005 $1
Q2 2005 $1
Q1 2005 $1
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.142B $0.032B
Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $137.409B 27.16
Medtronic (MDT) Ireland $121.535B 17.77
Stryker (SYK) United States $72.819B 26.70
Boston Scientific (BSX) United States $52.168B 25.43
Baxter (BAX) United States $39.788B 25.45
Zimmer Biomet Holdings (ZBH) United States $25.879B 16.57
Smith & Nephew SNATS (SNN) United Kingdom $17.424B 0.00
Canopy Growth (CGC) Canada $14.802B 0.00
ResMed (RMD) United States $14.533B 27.56
Aurora Cannabis (ACB) Canada $9.364B 66.07
Bio-Rad Laboratories (BIO) United States $9.204B 52.51
Hill-Rom Holdings (HRC) United States $6.966B 21.55
Perrigo (PRGO) Ireland $6.355B 10.30
Insulet (PODD) United States $5.761B 1943.60
GW Pharmaceuticals (GWPH) United Kingdom $4.977B 0.00
ICU Medical (ICUI) United States $4.744B 29.53
Haemonetics (HAE) United States $4.355B 38.63
Hutchison China MediTech (HCM) China $3.802B 0.00
Agios Pharmaceuticals (AGIO) United States $3.664B 0.00
Neogen (NEOG) United States $3.153B 48.42
NuVasive (NUVA) United States $2.938B 25.63
Quidel (QDEL) United States $2.527B 22.80
Aphria (APHA) $2.418B 107.33
National Vision Holdings (EYE) United States $2.298B 45.20
Cardiovascular Systems (CSII) United States $1.337B 960.00
HEXO (HEXO) $1.317B 0.00
VAREX IMAGING (VREX) United States $1.274B 24.95
Phibro Animal Health (PAHC) United States $1.273B 18.29
AtriCure (ATRC) United States $1.095B 0.00
MacroGenics (MGNX) United States $0.957B 0.00
Lantheus Holdings (LNTH) United States $0.914B 24.70
Cerus (CERS) United States $0.842B 0.00
Omeros (OMER) United States $0.836B 0.00
PetIQ (PETQ) United States $0.835B 23.90
NanoString Technologies (NSTG) United States $0.726B 0.00
Meridian Bioscience (VIVO) United States $0.716B 21.32
Eagle Pharmaceuticals (EGRX) United States $0.674B 22.95
OraSure Technologies (OSUR) United States $0.671B 29.41
TG Therapeutics (TGTX) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.587B 27.92
Evolus (EOLS) United States $0.577B 0.00
Surmodics (SRDX) United States $0.556B 80.90
Quanterix (QTRX) United States $0.531B 0.00
BioLife Solutions (BLFS) United States $0.350B 144.46
Insys Therapeutics (INSY) United States $0.342B 0.00
Vapotherm (VAPO) United States $0.335B 0.00
Rockwell Medical (RMTI) United States $0.325B 0.00
Utah Medical Products (UTMD) United States $0.313B 20.33
Bovie Medical (APYX) United States $0.271B 0.00
Owens & Minor (OMI) United States $0.265B 3.67
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.242B 0.00
Cytosorbents (CTSO) United States $0.237B 0.00
Fonar (FONR) United States $0.140B 7.48
Surface Oncology (SURF) United States $0.123B 0.00
Chimerix (CMRX) United States $0.103B 0.00
Female Health (VERU) United States $0.097B 0.00
Chembio Diagnostics (CEMI) United States $0.094B 0.00
InfuSystems Holdings (INFU) United States $0.089B 0.00
United-Guardian (UG) United States $0.087B 20.02
CAS Medical Systems (CASM) United States $0.071B 0.00
Neurotrope (NTRP) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.062B 18.50
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.036B 0.00
Valeritas Holdings (VLRX) United States $0.033B 0.00
Senestech (SNES) United States $0.032B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Akers Biosciences Inc (AKER) United States $0.012B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
NeuroMetrix (NURO) United States $0.008B 15.14